Cancer of unknown primary site: 20 questions to be answered.

Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic work-up. Aetiologically, CUP might either harbor primaries that cannot be detected by the standardized diagnostic investigations or carry distinct genetic and epigenetic aberrations. In this article we try to clarify the clinical and pathological enigma of CUP by answering 20 important questions related to this entity.

[1]  N. Pavlidis,et al.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray. , 2007, European journal of cancer.

[2]  N. Pavlidis,et al.  Carcinoma of Unknown Primary (CUP) , 2014 .

[3]  J. Hainsworth,et al.  Neuroendocrine carcinoma of unknown primary site. , 2009, Seminars in oncology.

[4]  J. Verweij,et al.  Carcinoma of unknown primary: identification of a treatable subset? , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Oien,et al.  Pathologic evaluation of unknown primary cancer. , 2009, Seminars in oncology.

[6]  M. Erlander,et al.  Molecular classification of unknown primary cancer. , 2009, Seminars in oncology.

[7]  M. Kodaira,et al.  Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  E. Felip,et al.  Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  N. Pavlidis,et al.  Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? , 2005, Acta oncologica.

[10]  M. Burgess,et al.  Prognostic factors in metastatic carcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[12]  J. Hainsworth,et al.  Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Varadhachary,et al.  Carcinoma of Unknown Primary , 2001 .

[14]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[15]  N. Pavlidis,et al.  Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence , 2009, Breast Cancer Research and Treatment.

[16]  N. Pavlidis,et al.  Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[17]  N. Pavlidis,et al.  Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. , 2008, Cancer treatment reviews.

[18]  N. Pavlidis,et al.  Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. , 2009, Cancer treatment reviews.

[19]  J. Hainsworth,et al.  Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. , 1986, Annals of internal medicine.

[20]  J. Hainsworth,et al.  Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. , 2009, The oncologist.

[21]  J. Ioannidis,et al.  Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. , 2009, Cancer treatment reviews.

[22]  K. Hess,et al.  Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Pavlidis,et al.  Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. , 2010, Critical reviews in oncology/hematology.